These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8437902)

  • 21. [Monoclonal antibodies and their clinical use].
    Rytwiński K
    Pediatr Pol; 1986 Feb; 61(2):116-22. PubMed ID: 3529024
    [No Abstract]   [Full Text] [Related]  

  • 22. Rapid tapering of cyclosporin to maximise the graft-versus-leukaemia effect.
    Shaw PJ; Afify Z
    Bone Marrow Transplant; 1999 Mar; 23(6):632-3. PubMed ID: 10217198
    [No Abstract]   [Full Text] [Related]  

  • 23. Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance.
    Waldmann H; Hale G; Cobbold S
    Philos Trans R Soc Lond B Biol Sci; 2001 May; 356(1409):659-63. PubMed ID: 11375069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blockade of acute grade IV skin and eye graft-versus-host disease by anti-interleukin-2 receptor monoclonal antibody in genoidentical bone marrow transplantation setting.
    Ozşahin H; Tuchschmid P; Lauener R; Waldvogel K; Nadal D; Seger RA
    Turk J Pediatr; 1998; 40(2):231-5. PubMed ID: 9677728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LF 08-0299 protects murine recipients of minor antigen disparate donor bone marrow from lethal graft-versus-host disease.
    Bruley-Rosset M; Churaqui E; Annat J; Dutartre P
    Transplant Proc; 1996 Dec; 28(6):3114-6. PubMed ID: 8962208
    [No Abstract]   [Full Text] [Related]  

  • 26. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of an anti-interleukine 2 receptor monoclonal antibody for GvHD prophylaxis in unrelated bone marrow transplantation. GEGMO Group.
    Belanger C
    Bone Marrow Transplant; 1993; 11 Suppl 1():112-3. PubMed ID: 8448532
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
    Hiraoka A; Ohashi Y; Okamoto S; Moriyama Y; Nagao T; Kodera Y; Kanamaru A; Dohy H; Masaoka T;
    Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen.
    Arslan O; Akan H; Koç H; Beksaç M; Ilhan O; Ozcan M; Yalçín S; Gürman G; Konuk N; Uysal A
    Bone Marrow Transplant; 1996 Jul; 18(1):261. PubMed ID: 8832034
    [No Abstract]   [Full Text] [Related]  

  • 31. Advances in immune-based therapies to improve solid organ graft survival.
    Rose SM; Turka L; Kerr L; Rotrosen D
    Adv Intern Med; 2001; 47():293-331. PubMed ID: 11795079
    [No Abstract]   [Full Text] [Related]  

  • 32. [Possibilities and limits of kidney transplantation].
    Brosig W
    Z Urol Nephrol; 1969 Dec; 62(12):947-54. PubMed ID: 4909340
    [No Abstract]   [Full Text] [Related]  

  • 33. Bone marrow transplantation in childhood acute lymphoblastic leukemia with closely matched family donors in Hong Kong.
    Yuen PM; Chik KW; Li CK; Shing MM; Lai H
    Transplant Proc; 1996 Jun; 28(3):1748-9. PubMed ID: 8658866
    [No Abstract]   [Full Text] [Related]  

  • 34. [Immunosuppressors].
    Sánchez-Fructuoso AI
    Nefrologia; 2008; 28 Suppl 5():21-5. PubMed ID: 18847416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graft-versus-host disease.
    Nijhawan A; Drolet BA
    Adv Dermatol; 2001; 17():115-39. PubMed ID: 11758114
    [No Abstract]   [Full Text] [Related]  

  • 36. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
    Przepiorka D; Devine S; Fay J; Uberti J; Wingard J
    Bone Marrow Transplant; 1999 Nov; 24(10):1053-6. PubMed ID: 10578154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Syngeneic graft-versus-host disease: a report of two cases and literature review.
    Latif T; Pohlman B; Kalaycio M; Sobecks R; Hsi ED; Andresen S; Bolwell BJ
    Bone Marrow Transplant; 2003 Sep; 32(5):535-9. PubMed ID: 12942102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody and pre- plus post-transplant prednisone treatments support T cell-depleted stem cell engraftment without drug-induced morbidity.
    D'Costa S; Hurwitz JL
    Bone Marrow Transplant; 2002 Apr; 29(7):553-6. PubMed ID: 11979302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic graft-versus-host disease: where is promise for the future?
    Weisdorf DJ
    Leukemia; 2005 Sep; 19(9):1532-5. PubMed ID: 15990863
    [No Abstract]   [Full Text] [Related]  

  • 40. Monoclonal antibodies for diagnosis and therapy of lymphoproliferative diseases.
    Campana D; Janossy G
    Turk J Pediatr; 1990; 32(2):143-51. PubMed ID: 2091372
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.